DWTX earnings date and last-quarter result: next report 2026-08-12, last quarter beat, P/E -0.14. Updated 2026-07-23.
Dogwood Therapeutics (DWTX) Research Hub
Dogwood Therapeutics (DWTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.11 USD (-0.89%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.14, market cap 0.00B. This hub links to the full technical, earnings and options research available for DWTX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.11 USD (-0.89%) |
| 52-week range | 1.07 USD – 2.8 USD |
| Trend regime | Range |
| 14-day RSI | 4.4 (Oversold) |
| Trailing P/E | -0.14 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for DWTX
Covered Call on DWTX: how it works, illustrative setup around the real 1.11 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DWTX: how it works, illustrative setup around the real 1.11 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DWTX: how it works, illustrative setup around the real 1.11 USD price, max profit/loss, breakeven and when to use it. Educational.
DWTX technical analysis: range, last 1.11 USD, RSI 4.4, 52w range 1.07 USD–2.8 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is DWTX in?
Dogwood Therapeutics (DWTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DWTX in an uptrend or downtrend?
As of 2026-10-26, DWTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DWTX's trailing P/E ratio?
DWTX's trailing P/E is -0.14, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does DWTX next report earnings?
DWTX is next scheduled to report earnings on 2026-08-12.